Advertisement
Tekmira Pharmaceuticals Corporation has announced today that Bristol-Myers Squibb Company has exercised an option to extend through 2009 the research collaboration between the two companies. The collaboration focuses on validating certain gene targets using small interfering RNA (siRNA) provided by Bristol-Myers Squibb and employing Tekmira's stable nucleic-acid lipid particle (SNALP) formulations to deliver the siRNA. Dr. Mark J. Murray, Tekmira's President and CEO, said, "Our continuing relationship with Bristol-Myers Squibb exemplifies our strategy of collaborating with the world's leading pharmaceutical companies to expand the potential applications of our SNALP technology. These collaborations also complement our internal product development programs as we advance our own proprietary RNAi therapeutics to treat serious human diseases."
Advertisement
Advertisement